Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-28 4:16 pm Purchase |
2024-03-21 | 13D | LENZ Therapeutics, Inc. LENZ |
RA Capital Management, L.P. | 4,250,856 16.600% |
4,250,856 (New Position) |
Filing History |
| 2024-03-25 4:18 pm Purchase |
2024-03-14 | 13G | Regulus Therapeutics Inc. RGLS |
RA Capital Management, L.P. | 6,250,000 9.500% |
6,250,000 (New Position) |
Filing History |
| 2024-03-25 4:17 pm Purchase |
2024-03-14 | 13G | Cybin Inc. CYBN |
RA Capital Management, L.P. | 1,529,988 7.700% |
1,529,988 (New Position) |
Filing History |
| 2024-03-18 4:46 pm Purchase |
2024-03-14 | 13D | Climb Bio, Inc. CLYM |
RA Capital Management, L.P. | 13,179,181 47.500% |
2,778 (+0.02%) |
Filing History |
| 2024-03-11 7:56 pm Unchanged |
2024-03-07 | 13D | PepGen Inc. PEPG |
RA Capital Management, L.P. | 10,695,135 33.100% |
0 (Unchanged) |
Filing History |
| 2024-03-06 6:54 pm Purchase |
2024-03-04 | 13D | Janux Therapeutics, Inc. JANX |
RA Capital Management, L.P. | 10,593,395 19.990% |
1,922,751 (+22.18%) |
Filing History |
| 2024-03-06 6:50 pm Purchase |
2024-03-04 | 13D | 89bio, Inc. ETNB |
RA Capital Management, L.P. | 14,254,298 14.800% |
1,378,443 (+10.71%) |
Filing History |
| 2024-02-27 4:19 pm Sale |
2024-02-23 | 13D | Connect Biopharma Holdings Limited CNTB |
RA Capital Management, L.P. | 0 0.000% |
-3,062,871 (Position Closed) |
Filing History |
| 2024-02-26 4:17 pm Purchase |
2024-02-16 | 13G | Larimar Therapeutics, Inc. LRMR |
RA Capital Management, L.P. | 6,045,351 9.500% |
6,045,351 (New Position) |
Filing History |
| 2024-02-22 7:07 pm Unchanged |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 6,809,404 5.200% |
0 (Unchanged) |
Filing History |
| 2024-02-21 4:17 pm Sale |
2024-02-19 | 13D | Icosavax, Inc. ICVX |
RA Capital Management, L.P. | 0 0.000% |
-5,985,843 (Position Closed) |
Filing History |
| 2024-02-14 9:08 pm Sale |
2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,095,136 6.100% |
-313,570 (-9.20%) |
Filing History |
| 2024-02-14 6:41 pm Purchase |
2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 3,472,106 9.990% |
1,417 (+0.04%) |
Filing History |
| 2024-02-14 6:35 pm Unchanged |
2023-12-31 | 13G | Orchard Therapeutics plc ORTX |
RA Capital Management, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 5:17 pm Purchase |
2024-02-12 | 13D | Werewolf Therapeutics, Inc. HOWL |
RA Capital Management, L.P. | 6,179,035 15.200% |
2,210,452 (+55.70%) |
Filing History |
| 2024-02-14 5:04 pm Unchanged |
2023-12-31 | 13G | Tourmaline Bio, Inc. TRML |
RA Capital Management, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 5:03 pm Sale |
2023-12-31 | 13G | Nektar Therapeutics NKTR |
RA Capital Management, L.P. | 0 0.000% |
-18,700,000 (Position Closed) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA Capital Management, L.P. | 4,163,211 9.700% |
1,373,490 (+49.23%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
RA Capital Management, L.P. | 5,551,295 18.700% |
1,777,778 (+47.11%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Chimerix, Inc. CMRX |
RA Capital Management, L.P. | 8,800,000 9.900% |
2,298,376 (+35.35%) |
Filing History |